Randomized phase II cancer clinical trials

Randomized Phase II Cancer Clinical Trials

Volumn , Issue , 2013, Pages 1-221

  Jung, Sin Ho ^a  

^a DUKE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84921662123     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/b14751     Document Type: Book

References (109)

1. Chang, M.N., Therneau, T.M., Wieand, H.S., and Cha, S.S. (1987). Designs for group sequential phase II clinical trials. Biometrics, 43, 865–874.
2. DeGroot, M.H. (1970). Optimal Statistical Decisions. McGraw-Hill, New York.
3. Gehan, E.A. (1961). The determination of the number of patients required in a follow-up trial of a new chemotherapeutic agent. Journal of Chronic Diseases, 13, 346–353.
4. Jung, S.H., Carey, M., and Kim, K.M. (2001). Graphical search for two-stage designs for phase II clinical trials. Controlled Clinical Trials, 22, 367– 372.
5. Simon, R. (1989). Optimal two-stage designs for phase II clinical trials. Controlled Clinical Trials, 10, 1–10.
6. Therneau, T.M., Wieand, H.S., and Chang, M. (1990). Optimal designs for a group sequential trial Biometrics, 46, 771–781.
7. Armitage, P. (1958). Numerical studies in the sequential estimation of a binomial parameter. Biometrika, 45, 1–15.
8. Chang, M.N., Gould, A.L., and Snapinn, S.M. (1995). P-values for group sequential testing. Biometrika, 82, 650–654.
9. Chang, M.N. and O’Brien, PC. (1985). Confidence intervals following group sequential trials. Controlled Clinical Trials, 7,18–26.
10. Chang, M.N., Therneau, T.M., Wieand, H.S., and Cha, S.S. (1987). Designs for group sequential phase II clinical trials. Biometrics, 43, 865–874.
11. Chang, M.N., Wieand, H.S., and Chang, V.T. (1989). The bias of the sample proportion following a group sequential phase II clinical trials. Statistics in Medicine, 8,563–570.
12. Clopper, C.J. and Pearson, E.S. (1934). The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika, 26, 404–413.
13. Cook, T.D. (2002). P-value adjustment in sequential clinical trials. Biometrics, 58, 1005–1011.
14. Duffy, D.E. and Santner, T.J. (1987). Confidence intervals for a binomial parameter based on multistage tests. Biometrics, 43, 81–93.
15. Emerson, S.S. and Fleming, T.R. (1990). Parameter estimation following group sequential hypothesis testing. Biometrika, 77, 875–892.
16. Fleming, T.R. (1982). One sample multiple testing procedure for phase II clinical trials. Biometrics, 38, 143–151.
17. Girshick, M.A., Mosteller, F., and Savage, L.J. (1946). Unbiased estimates for certain binomial sampling problems with application. Annals of Mathematical Statistics, 17, 13–23.
18. Green, S.J. and Dahlberg, S. (1992). Planned versus attained design in phase II clinical trials. Statistics in Medicine, 11, 853–862.
19. Herndon, J. (1998). A design alternative for two-stage, phase II, multicenter cancer clinical trials. Controlled Clinical Trials, 19, 440–450.
20. Herson, J. (1979). Predictive probability early termination plans for phase II clinical trials. Biometrics, 35, 775–783.
21. Jennison, C. and Turnbull, B.W. (1983). Confidence intervals for a binomial parameter following a multistage test with application to MIL-STD 105D and medical trials. Technometrics, 25, 49–58.
22. Jung, S.H. and Kim, K.M. (2004). On the estimation of the binomial probability in multistage clinical trials. Statistics in Medicine, 23, 881–896.
23. Lehmann, E.L. (1983). Theory of Point Estimation. Wiley, New York.
24. Liu, A. and Hall, W.J. (1999). Unbiased estimation following a group sequential test. Biometrika, 86, 71–78.
25. Schultz, J.R., Nichol, F.R., Elfring, G.L., and Weed, S.D. (1973). Multistage procedures for drug screening. Biometrics, 29, 293–300.
26. Simon, R. (1989). Optimal two-stage designs for phase II clinical trials. Controlled Clinical Trials, 10, 1–10.
27. Tsiatis, A.A., Rosner, G.L., and Mehta, C.R. (1984). Exact confidence intervals following a group sequential test. Biometrics, 40, 797–803.
28. Whitehead, J. (1986). On the bias of maximum likelihood estimation following a sequential test. Biometrika, 73, 573–581.
29. Aalen, O.O. (1978). Nonparametric inference for a family of counting processes. Annals of Statistics, 6,701–726.
30. Berry, G. (1983). The analysis of mortality by the subject-years methods. Biometrics, 39, 173–184.
31. Brookmeyer, R. and Crowley, J. (1982). A confidence interval for the median survival time. Biometrics, 38, 29–41.
32. Finkelstein, D.M., Muzikansky, A., and Schoenfeld, D.A. (2003). Comparing survival of a sample to that of a standard population. Journal of the National Cancer Institute, 95, 1434–1439.
33. Fleming, T.R. and Harrington, D.P. (1991). Counting Processes and Survival Analysis, Wiley, New York.
34. Gardiner, J., Susarla, V., and Van Ryzin, J. (1985). On the estimation of the median survival time under random censorship. In: Adaptive Statistical Procedures and Related Topics, IMS Lecture Notes, 8, 350–364.
35. Kaplan, E.L. and Meier, P. (1958). Nonparametric estimation from incomplete observations. Journal of the American Statistical Association, 53, 457– 481.
36. Miller, R.G. (1981). Survival Analysis, John Wiley & Sons, New York.
37. Nelson, W. (1969). Hazard plotting for incomplete failure data. Journal of Quality Technology, 1,27–52.
38. Owzar, K. and Jung, S.H. (2008). Designing phase II trials in cancer with time-to-event endpoints (with discussion). Clinical Trials, 5,209–221.
39. Sprott, D.A. (1973). Normal likelihoods and their relation to large sample theory of estimation. Biometrika 60, 457–465.
40. Tsiatis, A.A. (1982). Repeated significance testing for a general class of statistics used in censored survival analysis. Journal of American Statistical Society, 77, 855–861.
41. Chang, M., Jung, S.H., and Wu, S.S. (2012). Two-stage designs with additional futility tests for phase II clinical trials with heterogeneous patient populations. Sequential Analysis, inpress.
42. Jung, S.H., Chang, M., and Kang, S. (2012). Phase II cancer clinical trials with heterogeneous patient populations. Journal of Biopharmaceutical Statistics, 22, 312–328.
43. Jung, S.H., Lee, T.Y., Kim, K.M., and George, S. (2004). Admissible two-stage designs for phase II cancer clinical trials. Statistics in Medicine, 23, 561–569.
44. London, W.B. and Chang, M.N. (2005). One-and two-stage designs for stratified phase II clinical trials. Statistics in Medicine, 24, 2597–2611.
45. Simon, R. (1989). Optimal two-stage designs for phase II clinical trials. Controlled Clinical Trials, 10, 1–10.
46. Sposto, R. and Gaynon, P.S. (2009). An adjustment for for patient heterogeneity in the design of two-stage phase II trials. Statistics in Medicine, 28, 2566–2579.
47. Beckhofer, R.E. (1954). A single-sample multiple decision procedure for ranking means of normal populations with known variances. Annals of Mathematical Statistics, 25, 16–39.
48. Berger, R. and Boos, D.D. (1994). P values maximized over a confidence set for the nuisance parameter. Journal of American Statistical Association, 89, 1012–1016.
49. Cheung, Y.K. (2008). Simple sequential boundaries for treatment selection in multi-armed randomized clinical trials with a control. Biometrics, 64, 940–949.
50. Jung, S.H. and George, S.L. (2009). Between-arm comparisons in randomized phase II trials. Journal of Biopharmaceutical Statistics, 19, 456–468.
51. Liu, P.Y., LeBlanc, M., and Desai, M. (1999). False positive rates of randomized phase II designs. Controlled Clinical Trials, 20, 343–352.
52. Palmer, C.R. (1991). A comparative phase II clinical trials procedure for choosing the best of three treatments. Statistics in Medicine, 20, 1051– 1060.
53. Sargent, D.J. and Goldberg, R.M. (2001). A flexible design for multiple armed screening trials. Statistics in Medicine, 20, 1051–1060.
54. Simon, R., Wittes, R.E., Ellenberg, S.S. (1985). Randomized phase II clinical trials. Cancer Treatment Reports, 69, 1375–1381.
55. Steinberg, S.M. and Venzon, D.J. (2002). Early selection in a randomized phase II clinical trial. Statistics in Medicine, 21, 1711–1726.
56. Cannistra, S.A. (2009). Phase II trials in Journal of Clinical Oncology. Journal of Clinical Oncology, 27(19), 3073–3076.
57. Fisher, R.A. (1935). The logic of inductive inference (with discussion). Journal of Royal Statistical Society, 98, 39–82.
58. Gan, H.K., Grothey, A., Pond, G.P., Moore, M.J., Siu, L.L., and Sargent, D.J. (2010). Randomized phase II trials: Inevitable or inadvisable? Journal of Clinical Oncology, 28(15), 2641–2647.
59. Jung, S.H. (2008). Randomized phase II trials with a prospective control. Statistics in Medicine, 27, 568–583.
60. Jung S.H., Carey, M., and Kim, K.M. (2001). Graphical search for two-stage designs for phase II clinical trials. Control Clinical Trials, 22, 367–372.
61. Jung, S.H., Lee, T.Y., Kim, K.M., and George, S. (2004). Admissible two-stage designs for phase II cancer clinical trials. Statistics in Medicine, 23, 561–569.
62. Lee, J.J. and Feng, L. (2005). Randomized phase II designs in cancer clinical trials: Current status and future directions. Journal of Clinical Oncology, 23 (19), 4450–4457.
63. Rubinstein, L.V., Korn, E.L., Freidlin, B., Hunsberger, S., Ivy, S.P., and Smith, M.A. (2005). Design issues of randomized phase II trials and a proposal for phase II screening trials. Journal of Clinical Oncology, 23 (28), 7199–7206.
64. Simon, R. (1989). Optimal two-stage designs for phase II clinical trials. Controlled Clinical Trials, 10, 1–10.
65. Steinberg, S.M. and Venzon, D.J. (2002). Early selection in a randomized phase II clinical trial. Statistics in Medicine, 21, 1711–1726.
66. Thall, P.F., Simon, R., and Ellenberg, S.S. (1989). A two-stage design for choosing among several experimental treatments and a control in clinical trials. Biometrics, 45, 537–547.
67. Fisher, R.A. (1935). The logic of inductive inference (with discussion). Journal of Royal Statistical Society, 98, 39–82.
68. Jung, S.H., Lee, T.Y., Kim, K.M., and George, S. (2004). Admissible two-stage designs for phase II cancer clinical trials. Statistics in Medicine, 23, 561–569.
69. Simon, R. (1989). Optimal two-stage designs for phase II clinical trials. Controlled Clinical Trials, 10, 1–10.
70. Djulbegovic, B., Kumar, A., Soares, H.P., Hozo, I., Bepler, G., Clarke, M., Bennett, C.L. (2008). New cancer treatment successes identified in phase 3 randomized controlled trials conducted by the National Cancer Institute–Sponsored Cooperative Oncology Groups, 1955 to 2006. Archives of Internal Medicine, 168 (6), 632–642.
71. 2 tests. Biometrics, 10, 417–451.
72. Crans, G.G. and Schuster, J.J. (2008). How conservative is Fisher’s exact test? A quantitave evaluation of the two-sample comparative binomial trial. Statistics in Medicine, 27, 3598–3611.
73. Fisher, R.A. (1935). The logic of inductive inference (with discussion). Journal of Royal Statistical Society, 98, 39–82.
74. Gart, J.J. (1985). Approximate tests and interval estimation of the common relative risk in the combination of 2 × 2 tables. Biometrika, 72, 673–677.
75. Jung, S.H., Chow, S.C., and Chi, E.M. (2007). A note on sample size calculation based on propensity analysis in nonrandomized trials. Journal of Biopharmaceutical Statistics, 17, 35–41.
76. Li, S.H., Simon, R.M., and Gart, J.J. (1979). Small sample properties of the Mantel–Haenszel test. Biometrika, 66, 181–183.
77. Mantel, N. and Haenszel, W. (1959). Statistical aspects of the analysis of data from retrospective studies of disease. Journal of the National Cancer Institute, 22, 719–748.
78. Simon, R. (1989). Optimal two-stage designs for phase II clinical trials. Controlled Clinical Trials, 10, 1–10.
79. Westfall, P.H., Zaykin, D.V., and Young, S.S.(2002). Multiple tests for genetic effects in association studies. Methods in Molecular Biology, vol. 184 Biostatistical Methods, pp. 143–168. Stephen Looney, Ed., Humana Press, Toloway, NJ.
80. Aalen, O.O. (1978). Nonparametric inference for a family of counting processes. Annals of Statistics, 6,701–726.
81. Andersen, P.K., Borgan, O., Gill, R.D., and Kidding, N. (1982). Linear nonparametric tests for comparison of counting processes with application to censored survival data (with discussion). International Statistical Review, 50, 219–258.
82. Fleming, T.R. and Harrington, D.P. (1991). Counting Processes and Survival Analysis. Wiley, New York.
83. George, S.L. and Desu, M.M. (1973). Planning the size and duration of a trial studying the time to some critical event. Journal of Chronic Disease, 27, 15–24.
84. Lachin, J.M. (1981). Introduction to sample size determination and power analysis for clinical trials. Controlled Clinical Trials, 2,93–113.
85. Lachin, J.M. (2005). A review of methods for futility stopping based on conditional power. Statistics in Medicine, 24, 2747–2764.
86. Lakatos, E. (1977). Sample sizes based on the log-rank statistic in complex clinical trials. Biometrics, 64, 156–160.
87. Lakatos, E. (1988). Sample sizes based on the log-rank statistic in complex clinical trials. Biometrics, 44, 229–241.
88. Nelson, W. (1969). Hazard plotting for incomplete failure data. Journal of Quality Technology, 1,27–52.
89. Pampallona, S. and Tsiatis, A.A. (1994). Group sequential designs for one-sided and two-sided hypothesis testing with provision for early stopping in favor of the null hypothesis. Journal of Statistical Planning and Inference, 42, 19–35.
90. Pasternack, B.S. and Gilbert, H.S. (1971). Planning the duration of long-term survival time studies designed for accrual by cohorts. Journal of Chronic Disease, 24, 13–24.
91. Peto, R. and Peto, J. (1972). Asymptotically efficient rank invariant test procedures (with discussion). Journal of the Royal Statistical Society, Series A, 135, 185–206.
92. Rubinstein, L., Gail, M., and Santner, T. (1981). Planning the duration of a comparative clinical trial with loss to follow-up and a period of continued observation. Journal of Chronic Disease, 27, 15–24.
93. Schoenfeld, D.A. (1983). Sample size formula for the proportional hazards regression model. Biometrics, 39, 499–503.
94. Schoenfeld, D.A. and Tsiatis, A.A. (1987). A modified log rank test for highly stratified data. Biometrika, 74, 167–175.
95. Slud, E.V. and Wei, L.J. (1982). Two-sample repeated significance tests based on the modified Wilcoxon statistic. Journal of American Statistical Society, 77, 862–868.
96. Tsiatis, A.A. (1982). Repeated significance testing for a general class of statistics used in censored survival analysis. Journal of American Statistical Society, 77, 855–861.
97. Wieand, S., Schroeder, G., and O’Fallon, J.R. (1994). Stopping when the experimental regimen does not appear to help. Statistics in Medicine, 13, 1453–1458.
98. Yateman, N.A. and Skene, A.M. (1992). Sample size for proportional hazards survival studies with arbitrary patient entry and loss to follow-up distributions. Statistics in Medicine, 11, 1103–1113.
99. Aalen, O.O. (1978). Nonparametric inference for a family of counting processes. Annals of Statistics, 6,701–726.
100. Cox, D.R. (1972). Regression models and life tables (with discussion). Journal of Royal Statistical Society B, 34, 187–220.
101. Fleming, T.R. and Harrington, D.P. (1991). Counting Processes and Survival Analysis. Wiley, New York.
102. Gallamini, A., Hutchings, M., Rigacci, L., Specht, L., Merli, F., Hansen, M., Patti, C., Loft, A., Di Raimondo, F., D’Amore, F., Biggi, A., Vitolo, U., Stelitano, C., Sancetta, R., Trentin, L., Luminari, S., Iannitto, E., Viviani, S., Pierri, I., and Levis, A. (2007). Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin’s lymphoma: A report from a joint Italian-Danish study. Journal of Clinical Oncology, 25(24), 3746–3752.
103. Hutchings, M., Loft, A., Hansen, M., Pedersen, L.M., Buhl, T., Jurlander, J., Buus, S., Keiding, S., D’Amore, F., Boesen, A.M., Berthelsen, A.K., and Specht, L. (2006). FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood, 107 (1), 52–59.
104. Jung, S.H., Kang, S.J., McCall, L., and Blumenstein, B. (2005). Sample size computation for noninferiority log-rank test. Journal of Biopharmaceutical Statistics, 15, 957–967.
105. Jung, S.H., Kim, C., and Chow, S.C. (2008). Sample size calculation for the log-rank tests for multi-arm trials with a control. Journal of Korean Statistical Society, 37, 11–22.
106. Nelson, W. (1969). Hazard plotting for incomplete failure data. Journal of Quality Technology, 1,27–52.
107. Peto, R. and Peto, J. (1972). Asymptotically efficient rank invariant test procedures (with discussion). Journal of the Royal Statistical Society, Series A, 135, 185–206.
108. Schoenfeld, D.A. (1983). Sample size formula for the proportional hazards regression model. Biometrics, 39, 499–503.
109. Yateman, N.A. and Skene, A.M. (1992). Sample size for proportional hazards survival studies with arbitrary patient entry and loss to follow-up distributions. Statistics in Medicine, 11, 1103–1113.